ARCT Key Statistics, Chart & Performance
The current stock price of ARCT is 6.84 USD. In the past month the price decreased by -8.19%. In the past year, price decreased by -61.96%.
ARCT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.7 | 412.54B | ||
| AMGN | AMGEN INC | 15.62 | 183.97B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.89 | 122.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 18.05 | 85.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 828.43 | 55.82B | ||
| INSM | INSMED INC | N/A | 37.54B | ||
| NTRA | NATERA INC | N/A | 35.11B | ||
| BIIB | BIOGEN INC | 11.17 | 27.42B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 21.69B | ||
| INCY | INCYTE CORP | 17.22 | 21.71B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About ARCT
Company Profile
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The company is headquartered in San Diego, California and currently employs 174 full-time employees. The company went IPO on 2013-05-22. The firm with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. The company has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The firm's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Company Info
ARCTURUS THERAPEUTICS HOLDIN
10285 Science Center Drive
San Diego CALIFORNIA 92121 US
CEO: Joseph E. Payne
Employees: 174
Phone: 18589002660
ARCTURUS THERAPEUTICS HOLDIN / ARCT FAQ
Can you describe the business of ARCTURUS THERAPEUTICS HOLDIN?
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The company is headquartered in San Diego, California and currently employs 174 full-time employees. The company went IPO on 2013-05-22. The firm with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. The company has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The firm's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
What is the current price of ARCT stock?
The current stock price of ARCT is 6.84 USD. The price increased by 3.48% in the last trading session.
Does ARCT stock pay dividends?
ARCT does not pay a dividend.
What is the ChartMill rating of ARCTURUS THERAPEUTICS HOLDIN stock?
ARCT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is ARCT stock listed?
ARCT stock is listed on the Nasdaq exchange.
Can you provide the market cap for ARCTURUS THERAPEUTICS HOLDIN?
ARCTURUS THERAPEUTICS HOLDIN (ARCT) has a market capitalization of 194.32M USD. This makes ARCT a Micro Cap stock.
What is the Short Interest ratio of ARCTURUS THERAPEUTICS HOLDIN (ARCT) stock?
The outstanding short interest for ARCTURUS THERAPEUTICS HOLDIN (ARCT) is 29.32% of its float.
ARCT Technical Analysis
ARCT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ARCT. No worries on liquidiy or solvency for ARCT as it has an excellent financial health rating, but there are worries on the profitability.
ARCT Financial Highlights
Over the last trailing twelve months ARCT reported a non-GAAP Earnings per Share(EPS) of -2.46. The EPS decreased by -10.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.63% | ||
| ROE | -29.71% | ||
| Debt/Equity | 0 |
ARCT Forecast & Estimates
17 analysts have analysed ARCT and the average price target is 32.77 USD. This implies a price increase of 379.06% is expected in the next year compared to the current price of 6.84.
For the next year, analysts expect an EPS growth of 31.45% and a revenue growth -47.92% for ARCT